A single‐center, open‐label positron emission tomography study to evaluate brivaracetam and levetiracetam synaptic vesicle glycoprotein 2A binding in healthy volunteers

Brivaracetam (BRV) and levetiracetam (LEV) are antiepileptic drugs that bind synaptic vesicle glycoprotein 2A (SV2A). In vitro and in vivo animal studies suggest faster brain penetration and SV2A occupancy (SO) after dosing with BRV than LEV. We evaluated human brain penetration and SO time course of BRV and LEV at therapeutically relevant doses using the SV2A positron emission tomography (PET) tracer 11C‐UCB‐J (EP0074; NCT02602860).

[1]  J. Szaflarski,et al.  Efficacy and Safety of Intravenous Brivaracetam as a Treatment for Increased Seizure Activity in an Epilepsy Monitoring Unit , 2019, Epilepsy & Behavior.

[2]  T. Buclin,et al.  Intravenous brivaracetam in status epilepticus: Correlation between loading dose, plasma levels and clinical response , 2019, Epilepsy Research.

[3]  Koen Van Laere,et al.  Quantifying SV2A density and drug occupancy in the human brain using [11C]UCB-J PET imaging and subcortical white matter as reference tissue , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[4]  E. Trinka,et al.  Intravenous brivaracetam in status epilepticus: A retrospective single‐center study , 2018, Epilepsia.

[5]  P. Klein,et al.  A review of the pharmacology and clinical efficacy of brivaracetam , 2018, Clinical pharmacology : advances and applications.

[6]  Yiyun Huang,et al.  Kinetic evaluation and test–retest reproducibility of [11C]UCB-J, a novel radioligand for positron emission tomography imaging of synaptic vesicle glycoprotein 2A in humans , 2017, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[7]  J. Mercier,et al.  Discovery and development of SV2A PET tracers: Potential for imaging synaptic density and clinical applications. , 2017, Drug discovery today. Technologies.

[8]  F. Rosenow,et al.  Treatment of refractory and super-refractory status epilepticus with brivaracetam: A cohort study from two German university hospitals , 2017, Epilepsy & Behavior.

[9]  D. Spencer,et al.  Imaging synaptic density in the living human brain , 2016, Science Translational Medicine.

[10]  Richard E Carson,et al.  Synthesis and Preclinical Evaluation of 11C-UCB-J as a PET Tracer for Imaging the Synaptic Vesicle Glycoprotein 2A in the Brain , 2016, The Journal of Nuclear Medicine.

[11]  M. Wood,et al.  Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment , 2016, Epilepsia.

[12]  Richard E Carson,et al.  Brivaracetam, a selective high‐affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action , 2016, Epilepsia.

[13]  Philippe Ryvlin,et al.  Epilepsy: new advances , 2015, The Lancet.

[14]  X. Sauvage,et al.  Discovery of Heterocyclic Nonacetamide Synaptic Vesicle Protein 2A (SV2A) Ligands with Single‐Digit Nanomolar Potency: Opening Avenues towards the First SV2A Positron Emission Tomography (PET) Ligands , 2014, ChemMedChem.

[15]  Xiao Jin,et al.  Evaluation of motion correction methods in human brain PET imaging--a simulation study based on human motion data. , 2013, Medical physics.

[16]  M. Gillard,et al.  Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties. , 2011, European journal of pharmacology.

[17]  R. Kaminski,et al.  Targeting SV2A for discovery of antiepileptic drugs , 2010 .

[18]  Mark Slifstein,et al.  Measuring Drug Occupancy in the Absence of a Reference Region: The Lassen Plot Re-Visited , 2010, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[19]  D. Margineanu,et al.  Anti‐convulsive and anti‐epileptic properties of brivaracetam (ucb 34714), a high‐affinity ligand for the synaptic vesicle protein, SV2A , 2008, British journal of pharmacology.

[20]  Jean-Pierre Daurès,et al.  The prevalence of epilepsy and pharmacoresistant epilepsy in adults: A population‐based study in a Western European country , 2008, Epilepsia.

[21]  R. Kaminski,et al.  SV2A protein is a broad-spectrum anticonvulsant target: Functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy , 2008, Neuropharmacology.

[22]  M. Gillard,et al.  Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant protein. , 2006, European journal of pharmacology.

[23]  K. Nocka,et al.  The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[24]  N. Tzourio-Mazoyer,et al.  Automated Anatomical Labeling of Activations in SPM Using a Macroscopic Anatomical Parcellation of the MNI MRI Single-Subject Brain , 2002, NeuroImage.

[25]  Anne T. Berg,et al.  Epidemiology in Epilepsy. , 2001, Epilepsy currents.

[26]  P. Kwan,et al.  Early identification of refractory epilepsy. , 2000, The New England journal of medicine.

[27]  Alan C. Evans,et al.  Enhancement of MR Images Using Registration for Signal Averaging , 1998, Journal of Computer Assisted Tomography.

[28]  Y. M. Hart,et al.  Remission of epilepsy: results from the National General Practice Study of Epilepsy , 1995, The Lancet.

[29]  Peter Herscovitch,et al.  Comparison of Bolus and Infusion Methods for Receptor Quantitation: Application to [18F]Cyclofoxy and Positron Emission Tomography , 1993, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[30]  M. Feany,et al.  The synaptic vesicle protein SV2 is a novel type of transmembrane transporter , 1992, Cell.

[31]  R. Scheller,et al.  SV2, a brain synaptic vesicle protein homologous to bacterial transporters. , 1992, Science.

[32]  W. Hauser,et al.  The Epidemiology of Epilepsy in Rochester, Minnesota, 1935 Through 1967 , 1975, Epilepsia.